Volker Diehl

发表

Suppression of the tumorigenic growth of Burkitt's lymphoma cells in immunodeficient mice by cytokine gene transfer using EBV‐derived episomal expression vectors

V. Diehl, M. Pawlita, A. Polack, 2000, International journal of cancer.

A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivo

V. Diehl, M. Pfreundschuh, U. Şahin, 1993, International journal of cancer.

Prognostic factors in idiopathic (Primary) osteomyelofibrosis

R. Fischer, J. Thiele, H. Kvasnicka, 1997, Cancer.

Locoregional treatment of low‐grade B‐cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation

V. Diehl, H. Tesch, A. Gossmann, 2001, International journal of cancer.

Lack of BCL10 mutations in Hodgkin's disease‐derived cell lines

V. Diehl, D. Ré, J. Wolf, 2000, British journal of haematology.

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

A. Rosenwald, R. Greil, H. Eich, 2022, HemaSphere.

Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.

V. Diehl, P. Borchmann, M. von Wolff, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

CD30‐specific AB1‐AB2‐AB3 internal image antibody network: Potential use as anti‐idiotype vaccine against Hodgkin's lymphoma

V. Diehl, M. Pfreundschuh, C. Pohl, 1993, International journal of cancer.

Anti‐idiotype vaccine against Hodgkin's lymphoma: Induction of B‐ and T‐cell immunity across species barriers against cd30 antigen by murine monoclonal internal image antibodies

V. Diehl, M. Pfreundschuh, C. Pohl, 1992, International journal of cancer.

Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T‐cell leukemia and infectious mononucleosis

V. Diehl, A. Tschiersch, C. Pohl, 1990, International journal of cancer.

European Code Against Cancer and scientific justification: third version (2003).

H. Bartelink, R. Doll, M. Kogevinas, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

J. Armitage, V. Diehl, T. Lister, 1998, The New England journal of medicine.

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

V. Diehl, B. Coiffier, J. Radford, 1998, Blood.

Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?

H M Kvasnicka, V. Diehl, J. Thiele, 2005, Histology and histopathology.

Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) – a clinicopathological study

V. Diehl, J. Thiele, R. Fischer, 1999, Leukemia.

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.

V. Diehl, H. Tesch, M. Dietlein, 2001, Blood.

Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice.

C. von Kalle, V. Diehl, C. Fonatsch, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma

V. Diehl, L. Gissmann, H. zur Hausen, 1982, Journal of virology.

Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells.

V. Diehl, U. Holtick, C. Wickenhauser, 2001, Cancer research.

European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.

V. Diehl, N. Harris, E. Jaffe, 2000, Blood.

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.

V. Diehl, N. Harris, E. Jaffe, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Artificial sweeteners--do they bear a carcinogenic risk?

V. Diehl, M R Weihrauch, V Diehl, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

T-cell Non-Hodgkin's Lymphoma in Adults: Clinicopathological Characteristics, Response to Treatment and Prognostic Factors

V. Diehl, B. Salzberger, P. Staib, 2002, Leukemia & lymphoma.

Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells.

V. Diehl, K. Rajewsky, R. Küppers, 2000, Cancer research.

Epidemiology and etiology of Hodgkin's lymphoma.

V. Diehl, T. Zander, R. Thomas, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient.

V. Diehl, K. Rajewsky, R. Küppers, 1996, Blood.

Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95.

V. Diehl, A. Hofmann, A. Hofmann, 2000, Experimental hematology.

Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors.

V. Diehl, H. Tesch, M. Jücker, 1992, Leukemia & lymphoma.

Production of multiple cytokines by Hodgkin's disease derived cell lines

V. Diehl, H. Tesch, M. Jucker, 1992, Hematological oncology.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

V. Diehl, B. Dörken, M. Sieber, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?

V. Diehl, B. Salzberger, M. Reiser, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin 10 inhibits cytokine production of human AML cells.

V. Diehl, F. Westermann, H. Tesch, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Bingshu E. Chen, H. Eich, V. Diehl, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin

V. Diehl, V. Ghetie, S. Barth, 2000, Leukemia.

New drugs in the treatment of Hodgkin's disease.

V. Diehl, P. Borchmann, R. Schnell, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection.

V. Diehl, M. Sieber, B. Salzberger, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study Group.

V. Diehl, M. Sieber, U. Rüffer, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Heterogeneous expression of proto‐oncogenes in Hodgkin's disease derived cell lines

V. Diehl, H. Tesch, S. Poppema, 1990, Hematological oncology.

Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.

V. Diehl, M. Pfreundschuh, G. Martin, 1990, Cancer research.

Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.

V. Diehl, M. Pfreundschuh, P. Tazzari, 1990, Cancer research.

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group.

V. Diehl, J. Franklin, M. Sieber, 2000, Blood.

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

B. Krug, V. Diehl, J. Franklin, 2001, Annals of Hematology.

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy

V. Diehl, H. Tesch, R. Schröder, 1999, Bone Marrow Transplantation.

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

V. Diehl, B. Dörken, M. Sieber, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Occurrence of Epstein-Barr virus genomes in human lymphoblastoid cell lines.

V. Diehl, H. Hausen, U. Schneider, 1972, Nature: New biology.

An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.

V. Diehl, H. Abken, C. Pohl, 1998, Cancer research.

Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group.

V. Diehl, K. Hübner, J. Franklin, 1997, The American journal of pathology.

BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.

V. Diehl, M. Pfreundschuh, B. Lathan, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.

H. Eich, R. Müller, V. Diehl, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups.

V. Diehl, G. Klein, A. D. Schryver, 1970, Journal of the National Cancer Institute.

Expression of Epstein-Barr Virus Nuclear Antigen 1 Is Associated with Enhanced Expression of CD25 in the Hodgkin Cell Line L428

V. Diehl, E. Kieff, H. Tesch, 1999, Journal of Virology.

RELATION BETWEEN EPSTEIN-BARR VIRAL AND CELL MEMBRANE IMMUNOFLUORESCENCE IN BURKITT TUMOR CELLS

V. Diehl, G. Klein, W. Henle, 1968, The Journal of experimental medicine.

Efficacy and safety of antiemetics.

V. Diehl, M. Marty, Volker Diehl, 1994, Cancer treatment reviews.

Human chronic lymphocytic leukemia cells regularly express mRNAs of the protooncogenes lck and c-fgr.

H Tesch, V. Diehl, H. Tesch, 1991, Leukemia research.

V. Diehl, J. Thiele, A. Schmitt-Gräff, 2004, Histology and histopathology.

Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.

V. Diehl, H. Tesch, M. Reiser, 1999, Leukemia & lymphoma.

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.

V. Diehl, B. Dörken, Y. Ko, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines

C. Fonatsch, H. Kirchner, M. Schaadt, 1980, International journal of cancer.

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

V. Diehl, A. Bernareggi, P. Staib, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions.

H. Eich, V. Diehl, P. Borchmann, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group.

V. Diehl, S. Hofer, P. Borchmann, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.

V. Diehl, N. Schmitz, J. Franklin, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

V. Diehl, H. Tesch, A. Engert, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group.

V. Diehl, M. Sieber, A. Engert, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Deregulation of immunoglobulin gene transcription in the Hodgkin–Reed Sternberg cell line L1236

V. Diehl, U. Holtick, D. Ré, 2001, British journal of haematology.

Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients.

V. Diehl, J. Thiele, H. Kvasnicka, 2001, Pathology, research and practice.

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment.

V. Diehl, B. Lathan, H. Tesch, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group.

V. Diehl, J. Franklin, U. Paulus, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994.

R. Greil, V. Diehl, G. Kemmler, 1999, European journal of cancer.

Phase I study of intratumoral application of recombinant human tumor necrosis factor.

V. Diehl, M. Pfreundschuh, H. Steinmetz, 1989, European journal of cancer & clinical oncology.

L428 cells derived from Hodgkin's disease produce E rosette-inhibiting factor.

C. von Kalle, V. Diehl, U. Wirnitzer, 1990, Blood.

Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography.

V. Diehl, H. Tesch, H. Bohlen, 1997, Journal of immunological methods.

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.

M Sieber, A Engert, H. Eich, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells.

V. Diehl, H. Tesch, D. Voliotis, 1999, Blood.

Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML

V. Diehl, J. Franklin, H. Tesch, 1999, Annals of Hematology.

Histological features of prognostic significance in CML — an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow

V. Diehl, H. Stein, J. Thiele, 1993, Annals of Hematology.

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

V. Diehl, G. Brittinger, D. Huhn, 2001, Annals of Hematology.